Table 3 Adverse events occurring during Radium-223 treatment

From: RADTHYR: an open-label, single-arm, prospective multicenter phase II trial of Radium-223 for the treatment of bone metastases from radioactive iodine refractory differentiated thyroid cancer

Grade maximum
  1 2 3
Serious Adverse event N pat % N pat % N pat %
No Bone pain 8 80 . . 1 10
  Asthenia 6 60 2 20 . .
  Lymphopenia 2 20 2 20 2 20
  Leukopenia 3 30 1 10 1 10
  Pain 4 40 1 10 . .
  Anemia 5 50 . . . .
  Nausea 5 50 . . . .
  Febrile neutropenia 2 20 1 10 1 10
  Thrombocytopenia 3 30 . . . .
  GGT increased 1 10 1 10 . .
  Sore muscles 2 20 . . . .
  Viral disease 2 20 . . . .
  Diarrhea 2 20 . . . .
  Incontinence 2 20 . . . .
  Abscess . . . . 1 10
  Bilirubin increased 1 10 . . . .
  Creatinine increased 1 10 . . . .
  HTA 1 10 . . . .
  Hypertriglyceridemia 1 10 . . . .
  Hyperuricemia 1 10 . . . .
  Inguinal hernia surgery 1 10 . . . .
  Neutropenia 1 10 . . . .
  Paresthesia 1 10 . . . .
  Rash pustular 1 10 . . .  
  Tachycardia 1 10 . . .  
  Urea increased 1 10 . . .  
  Vertigo 1 10 . . .  
  Alteration of the general condition 1 10 . . .  
  Anorexia 1 10 . . .  
  Constipation 1 10 . . .  
Yes Thrombocytopenia* . . .   1 10
  1. *Related to acute myeloid leukemia of the patient